Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.
Researchers sought to determine whether myeloablative consolidation after induction therapy would improve PFS in patients with newly diagnosed primary central nervous system lymphoma.
Researchers sought to determine whether C-CAR039 would be safe and effective in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Researchers sought to determine whether adding bortezomib to bendamustine-rituximab induction therapy would improve survival in patients with mantle cell lymphoma.
Researchers sought to determine whether a combination therapy of romidepsin and lenalidomide would be effective as initial therapy for patients with PTCL.
Researchers sought to determine whether penpulimab would have efficacy and a low rate of serious AEs in patients with relapsed/refractory classic Hodgkin lymphoma.
Zynlonta (loncastuximab tesirine-lpyl) is a CD19-directed antibody and alkylating agent conjugate.
The approval was based on data from the single-arm, open-label phase 2 ZUMA-5 study.
Breyanzi is a CD19-directed genetically modified autologous T cell immunotherapy.
Chemotherapy agents such as vincristine sulfate injection, vinblastine sulfate injection, and vinorelbine tartrate injection should only be prepared in IV infusion bags.
